Israel’s AiVF Raises $25M For Its Fertility Intelligence Platform

Tel Aviv-based AI digital health company AiVF, announced on Wednesday the completion of a $25 million Series A funding round to fuel adoption of its AI-based digital embryology management platform EMA, in the US and Europe, to grow its workforce, and to continue innovating solutions for digital fertility care. 

The round was led by New York-based venture capital and private equity firm Insight Partners, alongside participation from the family office of WeWork co-founder Adam Neumann. 

The EMA platform provides optimized end-to-end in vitro fertilization procedures for individuals seeking assisted reproductive technologies for their family building. AiVF’s advanced machine learning and computer vision algorithms have the potential to shorten the time to pregnancy and increase the predictability and success rate of IVF. 

Clinical research results from European and US IVF clinics demonstrate that the EMA platform performs 50 times faster and is 48 percent more accurate than an embryologist. Following three years of extensive R&D, the platform has now been made available across Europe and Asia. AiVF expects a rapid deployment of its platform in response to the growing demand from fertility clinics for second generation IVF technologies. 

Founded by reproductive medicine experts Daniella Gilboa and Prof Daniel Seidman in 2018, AiVF is a medical technology company that streamlines the IVF embryo selection process by providing clinicians and embryologists with its fully automated, AI-powered decision support platform. The company partners with leading clinics around the world to advance research and innovation in the field of reproductive medicine.

“Our vision is to help individuals realize their dream to become families,” says Daniella Gilboa, co-founder and CEO of AiVF. “We are delivering innovative products to the market while enhancing the science of reproductive medicine to drive the next generation of fertility care.”

“We can now leverage data to augment expertly trained clinicians, drive efficiencies and provide a new level of fertility care for all,” said Prof. Daniel Seidman, co-founder and chief medical officer of AiVF.